大鼠中赛拉嗪与芬太尼过量的呼吸及心脏毒性
研究在成年Sprague-Dawley大鼠中经静脉给予赛拉嗪单用或联合芬太尼(150 μg/kg),赛拉嗪设0.1、1、10 mg/kg三个剂量,用开放气流体积描记法测通气与肺气体交换、遥测与超声心动图评估心血管功能。结果:0.1 mg/kg赛拉嗪联合芬太尼死亡率无增加(12.5% vs 芬太尼单用10.5%),但延长呼吸暂停;1 mg/kg使芬太尼死亡率升至62.5%,存活者呼吸逐步恢复、非存活者因呼吸衰竭继发心源性休克;10 mg/kg联合芬太尼100%致死,2-3分钟内快速心源性休克导致无脉电活动。结论:赛拉嗪剂量依赖性地增强芬太尼所致呼吸抑制与心血管崩溃。
要点
- 大鼠中赛拉嗪10 mg/kg联合芬太尼(150 μg/kg)100%致死,2-3分钟内快速心源性休克进展为无脉电活动。
- 赛拉嗪1 mg/kg联合芬太尼死亡率62.5%,非存活者因呼吸衰竭继发心源性休克,存活者呼吸逐步恢复。
- 赛拉嗪0.1 mg/kg联合芬太尼死亡率12.5%,芬太尼单用10.5%,死亡率无增加但呼吸暂停延长。
- 赛拉嗪0.1 mg/kg联合芬太尼降低芬太尼所致呼吸肌僵直与氧耗。
- 赛拉嗪单用0.1 mg/kg呈典型α2肾上腺素能激动剂表现,10 mg/kg转为显著持续高血压。
适用人群与场景
- 成年雄性及雌性Sprague-Dawley大鼠,经静脉给予赛拉嗪单用或联合芬太尼150 μg/kg。
- 赛拉嗪剂量选择0.1 mg/kg、1 mg/kg、10 mg/kg,与报告的人体暴露一致。
处置流程与药物剂量
- 赛拉嗪0.1 mg/kg、1 mg/kg或10 mg/kg单用或联合芬太尼150 μg/kg,经静脉推注给药。
红旗征与不能漏的情况
- 赛拉嗪10 mg/kg联合芬太尼可在2-3分钟内出现快速心源性休克并进展为无脉电活动,100%致死。
- 赛拉嗪1 mg/kg联合芬太尼时非存活者出现呼吸衰竭继发心源性休克。
研究设计与关键结果
- 研究类型:大鼠实验研究;成年雄雌Sprague-Dawley大鼠经静脉给予赛拉嗪单用或联合芬太尼150 μg/kg,赛拉嗪剂量0.1、1、10 mg/kg;用开放气流体积描记法测通气与肺气体交换,遥测与超声心动图评估心血管功能。
- 赛拉嗪0.1 mg/kg联合芬太尼死亡率12.5%,芬太尼单用死亡率10.5%,死亡率无增加,但呼吸暂停延长。
- 赛拉嗪0.1 mg/kg联合芬太尼降低芬太尼所致呼吸肌僵直与氧耗。
- 赛拉嗪1 mg/kg联合芬太尼死亡率62.5%,存活者呼吸逐步恢复,非存活者出现呼吸衰竭继发的心源性休克。
- 赛拉嗪10 mg/kg联合芬太尼死亡率100%,2-3分钟内快速心源性休克导致无脉电活动。
- 赛拉嗪单用0.1 mg/kg呈典型α2肾上腺素能激动剂表现,10 mg/kg出现显著持续高血压。
证据类型、等级与局限
- 证据类型:动物实验(大鼠)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Xylazine, a veterinary sedative, is an adulterant increasingly found in illicit fentanyl supplies. Yet, the dose-dependent effects of xylazine on fentanyl overdose remain poorly characterized. We sought to determine how xylazine modifies fentanyl-induced mortality, respiratory depression, and cardiovascular dysfunction in rats.
METHODS: Adult male and female Sprague-Dawley rats received non-lethal xylazine alone or combined with fentanyl (150 μg/kg) intravenously. For xylazine, three doses (0.1 mg/kg, 1 mg/kg, or 10 mg/kg) were chosen that produced a dose-dependent transition from a predominantly α2-adrenergic receptor agonist to a non-specific α-adrenergic receptor agonist effect, and are consistent with reported human exposures. Ventilation and pulmonary gas exchange were measured using an open-flow plethysmograph. Cardiovascular function was assessed via telemetry and echocardiography.
RESULTS: Bolus injection of xylazine alone at 0.1 mg/kg produced a typical profile of an α2-adrenergic agonist transitioning to a pronounced and persistent hypertension at 10 mg/kg. Xylazine dose-dependently potentiated the toxicity of fentanyl. Xylazine at 0.1 mg/kg with fentanyl showed no mortality increase (12.5% versus 10.5% fentanyl alone) despite prolonging apnea. Of note, this dose reduced fentanyl-induced rigidity of respiratory muscles and oxygen consumption. Xylazine at 1 mg/kg dramatically increased fentanyl mortality (62.5%), with survivors showing progressive respiratory recovery while non-survivors developed cardiogenic shock secondary to respiratory failure. Xylazine at 10 mg/kg with fentanyl was universally fatal (100%), causing a unique clinical syndrome, consisting of rapid cardiogenic shock leading to a pulseless electrical activity within 2-3 min.
DISCUSSION: Xylazine, when combined with a fentanyl overdose, has no increased mortality at 0.1 mg/kg, exacerbates hypoxemia-driven toxicity on breathing generation and cardiac function at 1 mg/kg, while producing an acute and very rapid lethal cardiocirculatory failure at 10 mg/kg.
CONCLUSION: Xylazine significantly potentiates fentanyl-induced respiratory depression and cardiovascular collapse in a dose-dependent manner in rats.
参考来源
- Lewis T, Judenherc-Haouzi A, Reinhardt A, et al. Respiratory and cardiac toxicity of xylazine and fentanyl overdose in rats. Clin Toxicol (Phila). 2026. PMID: 41557468. doi:10.1080/15563650.2025.2598328
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。